Morphosys Seeks US Listing To Cement Corporate Developments

MorphoSys AG, the Munich-based antibody biopharmaceutical company, has unveiled plans to also list on Nasdaq with a public offering of American Depositary Shares (ADSs), each equivalent to 0.25 of an ordinary share. The company’s F-1 registration statement reveals a plan to raise a maximum of $150m.

By listing the ADSs on Nasdaq, Morphosys hopes to increase its visibility in the US. Currently listed on the Frankfurt Stock Exchange, US investors account for about 49% of the company’s shareholder base. “While we do have US investors as shareholders, listing on Nasdaq would enable us to access additional investors